185 related articles for article (PubMed ID: 34279770)
1. Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion.
Han T; Sun Y; Liu Y; Yan C; Wang Y; Xu L; Liu K; Huang X; Zhang X
Front Med; 2021 Oct; 15(5):728-739. PubMed ID: 34279770
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].
Han TT; Liu Y; Chen Y; Zhang YY; Fu HX; Yan CH; Mo XD; Wang FR; Wang JZ; Han W; Chen YY; Chen H; Sun YQ; Cheng YF; Wang Y; Zhang XH; Huang XJ; Xu LP
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):458-464. PubMed ID: 37550200
[No Abstract] [Full Text] [Related]
3. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
[TBL] [Abstract][Full Text] [Related]
4. Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
Choi Y; Choi EJ; Lee JH; Lee KH; Jo JC; Park HS; Lee YJ; Seol M; Lee YS; Kang YA; Jeon M; Lee JH
Clin Transplant; 2021 Mar; 35(3):e14199. PubMed ID: 33349948
[TBL] [Abstract][Full Text] [Related]
5. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation.
Yerushalmi Y; Shem-Tov N; Danylesko I; Canaani J; Avigdor A; Yerushalmi R; Nagler A; Shimoni A
Haematologica; 2023 Jul; 108(7):1782-1792. PubMed ID: 36475520
[TBL] [Abstract][Full Text] [Related]
6. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.
Christopeit M; Kuss O; Finke J; Bacher U; Beelen DW; Bornhäuser M; Schwerdtfeger R; Bethge WA; Basara N; Gramatzki M; Tischer J; Kolb HJ; Uharek L; Meyer RG; Bunjes D; Scheid C; Martin H; Niederwieser D; Kröger N; Bertz H; Schrezenmeier H; Schmid C
J Clin Oncol; 2013 Sep; 31(26):3259-71. PubMed ID: 23918951
[TBL] [Abstract][Full Text] [Related]
7. Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution.
Tomonari A; Iseki T; Ooi J; Nagayama H; Sato H; Takahashi T; Ito K; Nagamura F; Uchimaru K; Takahashi S; Shirafuji N; Tojo A; Tani K; Asano S
Int J Hematol; 2002 Apr; 75(3):318-23. PubMed ID: 11999364
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
Kobayashi S; Kanda Y; Konuma T; Inamoto Y; Matsumoto K; Uchida N; Ikegame K; Miyamoto T; Doki N; Nakamae H; Katayama Y; Takahashi S; Shiratori S; Saito S; Kawakita T; Kanda J; Fukuda T; Atsuta Y; Kimura F
Bone Marrow Transplant; 2022 Jan; 57(1):43-50. PubMed ID: 34625663
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Swoboda R; Kulagin A; Velardi A; Sanz J; Labussière-Wallet H; Potter V; Kuball J; Sica S; Parovichnikova E; Bethge W; Maillard N; Platzbecker U; Stölzel F; Ciceri F; Mohty M
Bone Marrow Transplant; 2023 Sep; 58(9):1008-1016. PubMed ID: 37253804
[TBL] [Abstract][Full Text] [Related]
10. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
[TBL] [Abstract][Full Text] [Related]
11. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
12. [Outcome of haploidentical hematopoietic stem cell transplantation for refractory/relapsed acute leukemia].
Wang Y; Liu DH; Liu KY; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Fu HX; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):917-21. PubMed ID: 23363748
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
14. [Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
Xuan L; Fan ZP; Zhang Y; Xu N; Ye JY; Zhou X; Wang ZX; Sun J; Liu QF; Huang F
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):351-354. PubMed ID: 29747291
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
16. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
[No Abstract] [Full Text] [Related]
17. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Zhao P; Ni M; Ma D; Fang Q; Zhang Y; Li Y; Huang Y; Chen Y; Chai X; Zhan Y; Li Y; Kang Q; Zhao M; Liu M; Zhang F; Huang S; Wen S; Deng B; Wang J
Ann Hematol; 2022 Jan; 101(1):119-130. PubMed ID: 34568973
[TBL] [Abstract][Full Text] [Related]
19. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Guillaume T; Thépot S; Peterlin P; Ceballos P; Bourgeois AL; Garnier A; Orvain C; Giltat A; François S; Bris YL; Fronteau C; Planche L; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):839.e1-839.e6. PubMed ID: 34224913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
